BIVM-ERCC5: A Potential Drug Target and Biomarker (G100533467)

Target Name: BIVM-ERCC5

NCBI ID: G100533467

BIVM-ERCC5

Other Name(s): BIVM-ERCC5 protein | ERCC5-202 | DNA-repair protein complementing XP-G cells variant | BIVM-ERCC5 readthrough

BIVM-ERCC5: A Potential Drug Target and Biomarker

BIVM-ERCC5 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its name stands for Bcl-2-interactive gene variable 5, and it is a gene that encodes a protein known as BIVM-ERCC5. BIVM-ERCC5 plays a crucial role in the regulation of cell growth and differentiation, and its expression has been linked to the development and progression of various diseases.

Diseases and Their Connection to BIVM-ERCC5

One of the most significant connections to BIVM-ERCC5 is its role in the development and progression of cancer. BIVM-ERCC5 has been shown to be highly expressed in various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that BIVM-ERCC5 is involved in the regulation of cell cycle progression, which is a critical step in the development and progression of cancer.

In addition to its role in cancer development, BIVM-ERCC5 has also been linked to a number of other diseases and conditions. For example, BIVM-ERCC5 has been shown to be highly expressed in individuals with autoimmune diseases, such as rheumatoid arthritis and lupus. Additionally, BIVM-ERCC5 has been linked to a number of neurological conditions, including Alzheimer's disease and Parkinson's disease.

Potential Therapeutic Strategies

Given the various connections to BIVM-ERCC5, there is significant potential for developing therapeutic strategies against this gene. One potential approach is to target BIVM-ERCC5 directly with small molecules or antibodies that can modulate its expression. This approach would involve identifying small molecules or antibodies that can interact with BIVM-ERCC5 and modulate its activity.

Another potential approach is to target BIVM-ERCC5 via its role in cell cycle regulation. This could involve developing drugs that inhibit the activity of BIVM-ERCC5 and disrupt its ability to regulate cell cycle progression. This approach would be especially effective if BIVM-ERCC5 is involved in the regulation of a critical step in cell cycle, such as the G1 checkpoint.

Another approach could be to target BIVM-ERCC5 via its role in the regulation of inflammation. BIVM-ERCC5 has been shown to be involved in the regulation of inflammation and has been linked to the development of various inflammatory diseases. Therefore, drugs that can inhibit BIVM-ERCC5 activity in this context could be effective in treating autoimmune diseases.

Conclusion

In conclusion, BIVM-ERCC5 is a gene that has significant potential as a drug target and biomarker for various diseases, including cancer. Its role in the regulation of cell growth and differentiation, as well as its involvement in the development and progression of various diseases, make it an attractive target for therapeutic intervention. Further research is needed to fully understand the mechanisms of BIVM-ERCC5's role in disease and to develop effective therapeutic strategies against this gene.

Protein Name: BIVM-ERCC5 Readthrough

The "BIVM-ERCC5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BIVM-ERCC5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets